Clinical Trial Update: Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating KDT501 on metabolic features in insulin-resistant individuals with Type 2 diabetes has completed, with the study update issued.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• KDT501

Snippet

Sponsor: KinDex Pharmaceuticals, Inc. | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED